The Korean Dental Association announced on the 16th that it will operate a 'presidential election policy planning and promotion task force' (presidential planning group) ahead of the 21st presidential election on June 3. The association deliberated and decided on this matter at its 12th regular board meeting the previous day. The association explained that the task force will be operated to improve public oral health and address dental industry issues. Park Young-chae serves as the Director General, while Kang Chung-kyu and Lee Min-jung are the deputy directors. The presidential planning group will launch on the 23rd.
Prestige Biopharma announced on the 16th that a preclinical comparative evaluation paper for its trastuzumab biosimilar Tuznue has been published in the SCI-level international academic journal 'Drug in R&D.' Prestige Biopharma made its first announcement of the preclinical paper for Tuznue ahead of its overseas market entry. Chairman Park So-yeon and experts from the manufacturing and quality control team participated as co-authors.
Bio regeneration medical corporation CG Bio announced on the 16th that it has obtained export approval for its DNA-based skin booster product 'QB with PN.' This product utilizes polynucleotide (PN) components obtained by purifying DNA derived from salmon and fish. CG Bio plans to sell the skin booster in Japan, Hong Kong, and Chile while targeting the overseas market.
Daewon Pharmaceutical announced on the 16th that it has launched the anti-inflammatory pain reliever 'Saxinocool gel' (Saxinocool). It is easy to apply to contoured body parts like elbows, knees, and shoulders. This product contains the ingredient piroxicam. Unlike gel-type patches, it has less skin irritation and stickiness. It does not get on hands when applied like lotion. It is portable and suitable for people who often engage in outdoor activities.
Dong-A ST subsidiary Metavia announced on the 16th that it has proven the effectiveness of the obesity treatment 'DA-1726.' Metavia confirmed weight loss effects in the topline data from phase 1 part 2 clinical trials of DA-1726. After patients were administered 33 mg of the product, their weight dropped by as much as 6.3% (6.8 kg) in 4 weeks. The average weight loss effect was 4.3% (4 kg). Waist circumference decreased by a maximum of 10 cm and an average of 4 cm by day 33. No serious adverse events were reported. Mild symptoms such as nausea, vomiting, and constipation recovered within 24 hours. The company stated that it shows safety and tolerability.